Obesity and renal cell carcinoma: Epidemiology, underlying mechanisms and management considerations

Expert Review of Anticancer Therapy

Volumn 9, Issue 7, 2009, Pages 975-987

  Klinghoffer, Zachary ^a   Yang, Brian ^a   Kapoor, Anil ^a   Pinthus, Jehonathan H ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Adipokines; Adiponectin; Adipose tissue; BMI; IL 6; Kidney cancer; Leptin; Nephrectomy; Obesity; Renal cell carcinoma

Indexed keywords

BEVACIZUMAB; SORAFENIB; SUNITINIB;

HUMAN; HYPERTENSION; IMMUNOTHERAPY; INFLAMMATION; KIDNEY CARCINOMA; LIPID PEROXIDATION; NEPHRECTOMY; OBESITY; PROGNOSIS; REVIEW; RISK FACTOR;

EID: 69249135876     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.09.51     Document Type: Review

References (159)

1. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295, 1549-1555 (2006).
2. Ford ES, Mokdad AH. Epidemiology of obesity in the Western hemisphere. J. Clin. Endocrinol. Metab. 93, S1-S8 (2008).
3. Peytremann-Bridevaux I, Faeh D, Santos-Eggimann B. Prevalence of overweight and obesity in rural and urban settings of 10 European countries. Prev. Med. 44, 442-446 (2007).
4. McCann J. Obesity, cancer links prompt new recommendations. J. Natl Cancer Inst. 93, 901-902 (2001).
5. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer 4, 579-591 (2004).
6. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin. 58, 71-96 (2008).
7. Chow WH, Devesa SS, Warren JL, Fraumeni JF. Rising incidence of renal cell cancer in the United States. JAMA 281, 1628-1631 (1999).
8. Moyad MA. Review of potential risk factors for kidney (renal cell) cancer. Semin. Urol. Oncol. 19, 280-293 (2001).
9. Chow WH, Gridley G, Fraumeni JF, Järvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N. Engl J. Med. 343, 1305-1311 (2000).
10. Moore LE, Wilson RT, Campleman SL. Lifestyle factors, exposures, genetic susceptibility, and renal cell cancer risk: a review. Cancer Invest. 23, 240-255 (2005).
11. Devesa SS, Silverman DT, McLaughlin JK, Brown CC, Connelly RR, Fraumeni JF. Comparison of the descriptive epidemiology of urinary tract cancers. Cancer Causes Control 1, 133-141 (1990).
12. Pantuck AJ, Zisman A, Belldegrun A. Biology of renal cell carcinoma: changing concepts in classification and staging. Semin. Urol. Oncol. 19, 72-79 (2001).
13. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 89, 604-614 (2000).
14. Tosaka A, Ohya K, Yamada K et al. Incidence and properties of renal masses and asymptomatic renal cell carcinoma detected by abdominal ultrasonography. J. Urol. 144, 1097-1099 (1990).
15. Volpe A, Mattar K, Finelli A et al. Contemporary results of percutaneous biopsy of 100 small renal masses: a single center experience. J. Urol. 180, 2333-2337 (2008).
16. Volpe A, Jewett MA. The natural history of small renal masses. Nat. Clin. Pract. Urol. 2, 384-390 (2005).
17. Ishikawa I, Honda R, Yamada Y, Kakuma T. Renal cell carcinoma detected by screening shows better patient survival than that detected following symptoms in dialysis patients. Ther. Apher. Dial. 8, 468-473 (2004).
18. Neuzillet Y, Lay F, Luccioni A et al. De novo renal cell carcinoma of native kidney in renal transplant recipients. Cancer 103, 251-257 (2005).
19. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J. Urol. 166, 1611-1623 (2001).
20. Matin SF, Ahrar K. Nephron-sparing probe ablative therapy: long-term outcomes. Curr. Opin. Urol. 18, 150-156 (2008).
21. Goel RK, Kaouk JH. Probe ablative treatment for small renal masses: cryoablation vs radio frequency ablation. Curr. Opin. Urol. 18, 467-473 (2008).
22. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. CD001425 (2005).
23. Heng DY, Bukowski RM Anti-angiogenic targets in the treatment of advanced renal cell carcinoma. Curr. Cancer Drug Targets 8, 676-682 (2008).
24. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007).
25. Lichtenstein P, Holm NV, Verkasalo PK et al. Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 343, 78-85 (2000).
26. Pfaffenroth EC, Linehan WM. Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. Expert Opin. Biol. Ther. 8, 779-790 (2008).
27. Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J. Urol. 176, 2353-2358 (2006).
28. Decastro GJ, McKiernan JM. Epidemiology, clinical staging, and presentation of renal cell carcinoma. Urol. Clin. North Am. 35, 581-592, vi (2008).
29. Hunt JD, van der Hel OL, McMillan GP, Boffetta P, Brennan P. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int. J. Cancer 114, 101-108 (2005).
30. Vatten LJ, Trichopoulos D, Holmen J, Nilsen TI. Blood pressure and renal cancer risk: the HUNT study in norway. Br. J. Cancer 97, 112-114 (2007).
31. Weikert S, Boeing H, Pischon T et al. Blood pressure-and risk of renal cell carcinoma in the european prospective investigation into cancer and nutrition. Am. J. Epidemiol. 167, 438-446 (2008).
32. Chow WH, Devesa SS. Contemporary epidemiology of renal cell cancer. Cancer J. 14, 288-301 (2008).
33. Adams KF, Leitzmann MF, Albanes D et al. Body size and renal cell cancer incidence in a large US cohort study. Am. J. Epidemiol. 168, 268-277 (2008).
34. Bergström A, Hsieh CC, Lindblad P, Lu CM, Cook NR, Wolk A. Obesity and renal cell cancer - a quantitative review. Br. J. Cancer 85, 984-990 (2001).
35. Bjørge T, Tretli S, Engeland A. Relation of height and body mass index to renal cell carcinoma in two million Norwegian men and women. Am. J. Epidemiol. 160, 1168-1176 (2004).
36. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371, 569-578 (2008).
37. Setiawan VW, Stram DO, Nomura AM, Kolonel LN, Henderson BE. Risk factors for renal cell cancer: the multiethnic cohort. Am. J. Epidemiol. 166, 932-940 (2007).
38. Whittemore AS, Paffenbarger RS, Anderson K, Lee JE. Early precursors of site-specific cancers in college men and women. J. Natl Cancer Inst. 74, 43-51 (1985).
39. IARC Handbooks of Cancer Prevention. Volume 6: Weight Control and Physical Activity. Vainio H, Bianchini F (Eds). IARC Press, Lyon, France (2002).
40. Diehl AK. Epidemiology and natural history of gallstone disease. Gastroenterol. Clin. North Am. 20, 1-19 (1991).
41. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA 291, 844-850 (2004).
42. Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int. 65, 1870-1876 (2004).
43. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann. Intern. Med. 144, 21-28 (2006).
44. Gelber RP, Kurth T, Kausz AT et al. Association between body mass index and CKD in apparently healthy men. Am. J. Kidney Dis. 46, 871-880 (2005).
45. Kramer H. Screening for kidney disease in adults with diabetes and prediabetes. Curr. Opin. Nephrol. Hypertens. 14, 249-252 (2005).
46. Serra A, Romero R, Lopez D et al. Renal injury in the extremely obese patients with normal renal function. Kidney Int. 73, 947-955 (2008).
47. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J. Am. Soc. Nephrol. 17, 17-25 (2006).
48. Haase VH. The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease. Kidney Int. 69, 1302-1307 (2006).
49. Sharifi N, Farrar WL. Perturbations in hypoxia detection: a shared link between hereditary and sporadic tumor formation? Med. Hypotheses 66, 732-735 (2006).
50. Kourembanas S, Hannan RL, Faller DV. Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells. J. Clin. Invest. 86, 670-674 (1990).
51. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J. Clin. Oncol. 23, 1028-1043 (2005).
52. Griffin KA, Kramer H, Bidani AK. Adverse renal consequences of obesity. Am. J. Physiol. Renal Physiol. 294, F685-F696 (2008).
53. Kellerer M, von Eye Corleta H, Mühlhöfer A et al. Insulin- and insulin-like growth-factor-I receptor tyrosine-kinase activities in human renal carcinoma. Int. J. Cancer 62, 501-507 (1995).
54. Carroll VA, Ashcroft M. Role of hypoxia-inducible factor (HIF)-1α versus hif-2α in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res. 66, 6264-6270 (2006).
55. Rosendahl A, Forsberg G. Influence of IGF-IR stimulation or blockade on proliferation of human renal cell carcinoma cell lines. Int. J. Oncol. 25, 1327-1336 (2004).
56. Rosendahl AH, Forsberg G. IGF-I and IGFBP-3 augment transforming growth factor-β actions in human renal carcinoma cells. Kidney Int. 70, 1584-1590 (2006).
57. Lindblad P, Wolk A, Bergström R, Persson I, Adami HO. The role of obesity and weight fluctuations in the etiology of renal cell cancer: a population-based case-control study. Cancer Epidemiol. Biomarkers Prev. 3, 631-639 (1994).
58. Schlehofer B, Pommer W, Mellemgaard A et al. International renal-cell-cancer study. VI. The role of medical and family history. Int. J. Cancer 66, 723-726 (1996).
59. Dombrowski F, Klotz L, Bannasch P, Evert M. Renal carcinogenesis in models of diabetes in rats: metabolic changes are closely related to neoplastic development. Diabetologia 50, 2580-2590 (2007).
60. Vettor R, Milan G, Rossato M, Federspil G. Review article: adipocytokines and insulin resistance. Aliment. Pharmacol. Ther. 22(Suppl. 2), 3-10 (2005).
61. Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257, 79-83 (1999).
62. Pinthus JH, Kleinmann N, Tisdale B et al. Lower plasma adiponectin levels are associated with larger tumor size and metastasis in clear-cell carcinoma of the kidney. Eur. Urol. 54, 866-873 (2008).
63. Chatterjee S, Kleinman N, Gharajeh A et al. Computerized tomography measurement of visceral adiposity predicts plasma adiponectin levels and metastatic disease in patients with clear cell renal cell carcinoma. Curr. Urol. 2, 188-193 (2008).
64. Koo AS, Armstrong C, Bochner B et al. Interleukin-6 and renal cell cancer: production, regulation, and growth effects. Cancer Immunol. Immunother. 35, 97-105 (1992).
65. Costes V, Liautard J, Picot MC et al. Expression of the interleukin 6 receptor in primary renal cell carcinoma. J. Clin. Pathol. 50, 835-840 (1997).
66. Steiner T, Junker U, Wunderlich H, Schubert J. Are renal cell carcinoma cells able to modulate the cytotoxic effect of tumor infiltrating lymphocytes by secretion of interleukin-6? Anticancer Res. 19, 1533-1536 (1999).
67. Horiguchi A, Sumitomo M, Asakuma J et al. Increased serum leptin levels and over expression of leptin receptors are associated with the invasion and progression of renal cell carcinoma. J. Urol. 176, 1631-1635 (2006).
68. Li L, Gao Y, Zhang LL, He DL. Concomitant activation of the JAK/STAT3 and ERK1/2 signaling is involved in leptin-mediated proliferation of renal cell carcinoma caki-2 cells. Cancer Biol. Ther. 7 (2008).
69. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89, 2548-2556 (2004).
70. Sanz P. Amp-activated protein kinase: structure and regulation. Curr. Protein Pept. Sci. 9, 478-492 (2008).
71. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to c1q, produced exclusively in adipocytes. J. Biol. Chem. 270, 26746-26749 (1995).
72. Miyoshi Y, Funahashi T, Kihara S et al. Association of serum adiponectin levels with breast cancer risk. Clin. Cancer Res. 9, 5699-5704 (2003).
73. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J. Natl Cancer Inst. 97, 1688-1694 (2005).
74. Dal Maso L, Augustin LS, Karalis A et al. Circulating adiponectin and endometrial cancer risk. J. Clin. Endocrinol. Metab. 89, 1160-1163 (2004).
75. Michalakis K, Williams CJ, Mitsiades N et al. Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol. Biomarkers Prev. 16, 308-313 (2007).
76. Spyridopoulos TN, Petridou ET, Skalkidou A et al. Low adiponectin levels are associated with renal cell carcinoma: a case - control study. Int. J. Cancer 120, 1573-1578 (2007).
77. Bråkenhielm E, Veitonmäki N, Cao R et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc. Natl Acad. Sci. USA 101, 2476-2481 (2004).
78. Barb D, Pazaitou-Panayiotou K, Mantzoros CS. Adiponectin: a link between obesity and cancer. Expert Opin. Investig. Drugs 15, 917-931 (2006).
79. Konturek PC, Burnat G, Rau T, Hahn EG, Konturek S. Effect of adiponectin and ghrelin on apoptosis of Barrett adenocarcinoma cell line. Dig. Dis. Sci. 53, 597-605 (2008).
80. Wang Y, Lam KS, Xu JY et al. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J. Biol. Chem. 280, 18341-18347 (2005).
81. Arita Y, Kihara S, Ouchi N et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105, 2893-2898 (2002).
82. Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-α and IL-6. Diabetes Res. Clin. Pract. 69, 29-35 (2005).
83. Sievers E, Dreimuller P, Haferkamp A et al. Characterization of primary renal carcinoma cultures. Urol. Int. 79, 235-243 (2007).
84. Clapham JC, Smith SA, Moore GB et al. Plasma leptin concentrations and OB gene expression in subcutaneous adipose tissue are not regulated acutely by physiological hyperinsulinaemia in lean and obese humans. Int. J. Obes. Relat. Metab. Disord. 21, 179-183 (1997).
85. Jéjuier E. Leptin signaling, adiposity, and energy balance. Ann. NY Acad. Sci. 967, 379-388 (2002).
86. Beales IL, Ogunwobi OO. Leptin synergistically enhances the anti-apoptotic and growth-promoting effects of acid in OE33 oesophageal adenocarcinoma cells in culture. Mol. Cell. Endocrinol. 274, 60-68 (2007).
87. Hoda MR, Popken G. Mitogenic and anti-apoptotic actions of adipocyte-derived hormone leptin in prostate cancer cells. BJU Int. 102, 383-388 (2008).
88. Perera CN, Chin HG, Duru N, Camarillo IG. Leptin-regulated gene expression in MCF-7 breast cancer cells: mechanistic insights into leptin-regulated mammary tumor growth and progression. J. Endocrinol. 199, 221-233 (2008).
89. Birmingham JM, Busik JV, Hansen-Smith FM, Fenton JI. Novel mechanism for obesity-induced colon cancer progression. Carcinogenesis 30(4), 690-697 (2009).
90. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 394, 897-901 (1998).
91. Rasmuson T, Grankvist K, Jacobsen J, Olsson T, Ljungberg B. Serum insulin-like growth factor-1 is an independent predictor of prognosis in patients with renal cell carcinoma. Acta Oncol. 43, 744-748 (2004).
92. Mistry T, Digby JE, Desai KM, Randeva HS. Leptin and adiponectin interact in the regulation of prostate cancer cell growth via modulation of p53 and bcl-2 expression. BJU Int. 101, 1317-1322 (2008).
93. Fenton JI, Birmingham JM, Hursting SD, Hord NG. Adiponectin blocks multiple signaling cascades associated with leptin-induced cell proliferation in Ape min/+ colon epithelial cells. Int. J. Cancer 122, 2437-2445 (2008).
94. Key TJ, Appleby PN, Reeves GK et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J. Natl Cancer Inst. 95, 1218-1226 (2003).
95. Lukanova A, Lundin E, Zeleniuch-Jacquotte A et al. Body mass index, circulating levels of sex-steroid hormones, IGF-I and igf-binding protein-3: a cross-sectional study in healthy women. Eur. J. Endocrinol. 150, 161-171 (2004).
96. Stadler W, Vogelzang NJ. Human renal cancer carcinogenesis: a review of recent advances. Ann. Oncol. 4, 451-462 (1993).
97. Hodgson AV, Ayala-Torres S, Thompson EB, Liehr JG. Estrogen-Induced microsatellite DNA alterations are associated with Syrian hamster kidney tumorigenesis. Carcinogenesis 19, 2169-2172 (1998).
98. Tanaka Y, Sasaki M, Kaneuchi M, Fujimoto S, Dahiya R. Estrogen receptor-α polymorphisms and renal cell carcinoma - a possible risk. Mol. Cell. Endocrinol. 202, 109-116 (2003).
99. Ogushi T, Takahashi S, Takeuchi T et al. Estrogen receptor-binding fragment-associated antigen 9 is a tumor-promoting and prognostic factor for renal cell carcinoma. Cancer Res. 65, 3700-3706 (2005).
100. McLaughlin JK, Lipworth L, Tarone RE. Epidemiologic aspects of renal cell carcinoma. Semin. Oncol. 33, 527-533 (2006).
101. Gago-Dominguez M, Castelao JE. Lipid peroxidation and renal cell carcinoma: further supportive evidence and new mechanistic insights. Free Radic. Biol. Med. 40, 721-733 (2006).
102. Salonen R, Nyssönen K, Porkkala-Sarataho E, Salonen JT. The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am. J. Cardiol. 76, 34C-39C (1995).
103. Girona J, La Ville AE, Solà R, Plana N, Masana L. Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am. J. Cardiol. 83, 846-851 (1999).
104. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J. Clin. Oncol. 22, 2388-2394 (2004).
105. Fain JN. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam. Horm. 74, 443-477 (2006).
106. Wong LY, Leung RY, Ong KL, Cheung BM. Plasma levels of fibrinogen and c-reactive protein are related to interleukin-6 gene-572C>G polymorphism in subjects with and without hypertension. J. Hum. Hypertens. 21, 875-882 (2007).
107. Solá E, Jover A, López-Ruiz A et al. Parameters of inflammation in morbid obesity: lack of effect of moderate weight loss. Obes. Surg. 19(5), 571-576 (2009).
108. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am. J. Physiol. Heart Circ. Physiol. 288, H2031-H2041 (2005).
109. Karakiewicz PI, Hutterer GC, Trinh QD et al. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer 110, 1241-1247 (2007).
110. Komai Y, Saito K, Sakai K, Morimoto S. Increased preoperative serum c-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int. 99, 77-80 (2007).
111. Lamb GW, McArdle PA, Ramsey S et al. The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer. BJU Int. 102, 756-761 (2008).
112. Iimura Y, Saito K, Fujii Y et al. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J. Urol. 181, 1004-1012; discussion 1012 (2009).
113. Jabs WJ, Busse M, Krüger S, Jocham D, Steinhoff J, Doehn C. Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int. 68, 2103-2110 (2005).
114. Lew EA, Garfinkel L. Variations in mortality by weight among 750,000 men and women. J. Chronic Dis. 32, 563-576 (1979).
115. Donat SM, Salzhauer EW, Mitra N, Yanke BV, Snyder ME, Russo P. Impact of body mass index on survival of patients with surgically treated renal cell carcinoma. J. Urol. 175, 46-52 (2006).
116. Awakura Y, Nakamura E, Ito N et al. Influence of body mass index on prognosis of Japanese patients with renal cell carcinoma. Urology 70, 50-54 (2007).
117. Kamat AM, Shock RP, Naya Y, Rosser CJ, Slaton JW, Pisters LL. Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors. Urology 63, 46-50 (2004).
118. Parker AS, Lohse CM, Cheville JC, Thiel DD, Leibovich BC, Blute ML. Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma. Urology 68, 741-746 (2006).
119. Schips L, Lipsky K, Zigeuner R et al. Does overweight impact on the prognosis of patients with renal cell carcinoma? A single center experience of 683 patients. J. Surg. Oncol. 88, 57-61; discussion 61-62 (2004).
120. Yu ML, Asal NR, Geyer JR. Later recurrence and longer survival among obese patients with renal cell carcinoma. Cancer 68, 1648-1655 (1991).
121. Bonora E, Micciolo R, Ghiatas AA et al. Is it possible to derive a reliable estimate of human visceral and subcutaneous abdominal adipose tissue from simple anthropometric measurements? Metabolism 44, 1617-1625 (1995).
122. Romero-Corral A, Montori VM, Somers VK et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet 368, 666-678 (2006).
123. Oh TH, Byeon JS, Myung SJ et al. Visceral obesity as a risk factor for colorectal neoplasm. J. Gastroenterol. Hepatol. 23, 411-417 (2008).
124. Poirier P, Després JP. Waist circumference, visceral obesity, and cardiovascular risk. J. Cardiopulm. Rehabil. 23, 161-169 (2003).
125. Haferkamp A, Pritsch M, Bedke J et al. The influence of body mass index on the long-term survival of patients with renal cell carcinoma after tumour nephrectomy. BJU Int. 101, 1243-1246 (2008).
126. St-Onge MP, Janssen I, Heymsfield SB. Metabolic syndrome in normal-weight Americans: new definition of the metabolically obese, normal-weight individual. Diabetes Care 27, 2222-2228 (2004).
127. Karakiewicz PI, Suardi N, Capitanio U et al. A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur. Urol. DOI: 10.1016/j.eururo.2008.07.037 (2008).
128. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J. Urol. 166, 63-67 (2001).
129. Zisman A, Pantuck AJ, Dorey F et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J. Clin. Oncol. 19, 1649-1657 (2001).
130. Anderson CF, Velosa JA, Frohnert PP et al. The risks of unilateral nephrectomy: status of kidney donors 10 to 20 years postoperatively. Mayo Clin. Proc. 60, 367-374 (1985).
131. Goldfarb DA, Matin SF, Braun WE et al. Renal outcome 25 years after donor nephrectomy. J. Urol. 166, 2043-2047 (2001).
132. Najarian JS, Chavers BM, McHugh LE, Matas AJ. 20 years or more of follow-up of living kidney donors. Lancet 340, 807-810 (1992).
133. Praga M, Hernández E, Herrero JC et al. Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int. 58, 2111-2118 (2000).
134. González E, Gutiérrez E, Morales E et al. Factors influencing the progression of renal damage in patients with unilateral renal agenesis and remnant kidney. Kidney Int. 68, 263-270 (2005).
135. Rook M, Bosma RJ, van Son WJ et al. Nephrectomy elicits impact of age and BMI on renal hemodynamics: lower postdonation reserve capacity in older or overweight kidney donors. Am. J. Transplant. 8, 2077-2085 (2008).
136. Young A, Storsley L, Garg AX et al. Health outcomes for living kidney donors with isolated medical abnormalities: a systematic review. Am. J. Transplant. 8, 1878-1890 (2008).
137. Espinoza R, Gracida C, Cancino J, Ibarra A. Effect of obese living donors on the outcome and metabolic features in recipients of kidney transplantation. Transplant Proc. 38, 888-889 (2006).
138. Gracida C, Espinoza R, Cedillo U, Cancino J. Kidney transplantation with living donors: nine years of follow-up of 628 living donors. Transplant Proc. 35, 946-947 (2003).
139. Mehrabi A, Fonouni H, Wente M et al. Wound complications following kidney and liver transplantation. Clin. Transplant. 20(Suppl. 17), 97-110 (2006).
140. Shuford MD, McDougall EM, Chang SS, LaFleur BJ, Smith JA, Cookson MS. Complications of contemporary radical nephrectomy: comparison of open vs laparoscopic approach. Urol. Oncol. 22, 121-126 (2004).
141. Canes D. Long-term oncological outcomes of laparoscopic partial nephrectomy. Curr. Opin. Urol. 18, 145-149 (2008).
142. Borin JF. Laparoscopic radical nephrectomy: long-term outcomes. Curr. Opin. Urol. 18, 139-144 (2008).
143. Feder MT, Patel MB, Melman A, Ghavamian R, Hoenig DM. Comparison of open and laparoscopic nephrectomy in obese and nonobese patients: outcomes stratified by body mass index. J. Urol. 180, 79-83 (2008).
144. Fazeli-Matin S, Gill IS, Hsu TH, Sung GT, Novick AC. Laparoscopic renal and adrenal surgery in obese patients: comparison to open surgery. J. Urol. 162, 665-669 (1999).
145. Mendoza D, Newman RC, Albala D et al. Laparoscopic complications in markedly obese urologic patients (a multi-institutional review). Urology 48, 562-567 (1996).
146. Fugita OE, Chan DY, Roberts WW, Kavoussi LR, Jarrett TW. Laparoscopic radical nephrectomy in obese patients: outcomes and technical considerations. Urology 63, 247-252; discussion 252 (2004).
147. Anast JW, Stoller ML, Meng MV et al. Differences in complications and outcomes for obese patients undergoing laparoscopic radical, partial or simple nephrectomy. J. Urol. 172, 2287-2291 (2004).
148. Kapoor A, Nassir A, Chew B, Gillis A, Luke P, Whelan P. Comparison of laparoscopic radical renal surgery in morbidly obese and non-obese patients. J. Endourol. 18, 657-660 (2004).
149. Parker AS, Lewis R, Heckman MG et al. Evaluation of the impact of body mass index on outcome among renal mass patients treated with hand-assisted laparoscopic radical nephrectomy. J. Endourol. 22, 301-306 (2008).
150. Romero FR, Rais-Bahrami S, Muntener M, Brito FA, Jarrett TW, Kavoussi LR. Laparoscopic partial nephrectomy in obese and non-obese patients: comparison with open surgery. Urology 71, 806-809 (2008).
151. Colombo JR, Haber GP, Aron M, Xu M, Gill IS. Laparoscopic partial nephrectomy in obese patients. Urology 69, 44-48 (2007).
152. McDermott DF, Atkins MB. Immunotherapy of metastatic renal cell carcinoma. Cancer J. 14, 320-324 (2008).
153. Choueiri TK, Garcia JA, Elson P et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated witR vascular endothelial growth factor-targeted therapy. Cancer 110, 543-550 (2007).
154. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13, 688-696 (1995).
155. Rini BI. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin. Cancer Res. 13, 1098-1106 (2007).
156. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 9, 117-123 (2008).
157. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 13, 1084-1096 (2008).
158. Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol. 48, 9-17 (2009).
159. Bellmunt J, Szczylik C, Feingold J, Strahs A, Berkenblit A. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann. Oncol. 19, 1387-1392 (2008).